CA3019682A1 - Traitement du carcinome a cellules renales a l'aide de lenvatinib et d'everolimus - Google Patents

Traitement du carcinome a cellules renales a l'aide de lenvatinib et d'everolimus Download PDF

Info

Publication number
CA3019682A1
CA3019682A1 CA3019682A CA3019682A CA3019682A1 CA 3019682 A1 CA3019682 A1 CA 3019682A1 CA 3019682 A CA3019682 A CA 3019682A CA 3019682 A CA3019682 A CA 3019682A CA 3019682 A1 CA3019682 A1 CA 3019682A1
Authority
CA
Canada
Prior art keywords
grade
dosage regimen
adverse reaction
persistent
everolimus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3019682A
Other languages
English (en)
Inventor
Alton KREMER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of CA3019682A1 publication Critical patent/CA3019682A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des méthodes et des compositions destinées à traiter un carcinome à cellules rénales à l'aide d'une association de lenvatinib ou d'un sel pharmaceutiquement acceptable de celui-ci et d'évérolimus. Des dosages et des modifications de doses particulièrement utiles lors de l'apparition d'effets indésirables sont en outre décrits.
CA3019682A 2016-04-15 2017-04-17 Traitement du carcinome a cellules renales a l'aide de lenvatinib et d'everolimus Pending CA3019682A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322916P 2016-04-15 2016-04-15
JP2016081787 2016-04-15
US62/322916 2016-04-15
JP2016-081787 2016-04-15
PCT/JP2017/015461 WO2017179739A1 (fr) 2016-04-15 2017-04-17 Traitement du carcinome à cellules rénales à l'aide de lenvatinib et d'évérolimus

Publications (1)

Publication Number Publication Date
CA3019682A1 true CA3019682A1 (fr) 2017-10-19

Family

ID=60041779

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3019682A Pending CA3019682A1 (fr) 2016-04-15 2017-04-17 Traitement du carcinome a cellules renales a l'aide de lenvatinib et d'everolimus

Country Status (7)

Country Link
EP (1) EP3442532A4 (fr)
KR (1) KR20180129795A (fr)
CN (1) CN108883106A (fr)
AU (1) AU2017249459A1 (fr)
CA (1) CA3019682A1 (fr)
SG (1) SG11201808774RA (fr)
WO (1) WO2017179739A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109793736A (zh) * 2019-01-31 2019-05-24 徐州医科大学 一种乐伐替尼在制备自然杀伤细胞激动剂中的应用
WO2021262562A2 (fr) * 2020-06-17 2021-12-30 Merck Sharp & Dohme Corp. Méthodes de traitement du cancer ou de la maladie de von hippel-lindau à l'aide d'une combinaison d'un antagoniste de pd-1, d'un inhibiteur de hif-2 alpha et de lenvatinib ou d'un sel pharmaceutiquement acceptable associé

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100804566B1 (ko) * 2003-12-25 2008-02-20 에자이 알앤드디 매니지먼트 가부시키가이샤 4-(3-클로로-4-(시클로프로필아미노카르보닐)아미노페녹시)-7-메톡시-6-퀴놀린카르복사미드의 염 또는 그 용매화물의 결정 및 이들의 제조 방법

Also Published As

Publication number Publication date
SG11201808774RA (en) 2018-11-29
EP3442532A4 (fr) 2019-12-11
AU2017249459A1 (en) 2018-10-25
KR20180129795A (ko) 2018-12-05
WO2017179739A1 (fr) 2017-10-19
CN108883106A (zh) 2018-11-23
EP3442532A1 (fr) 2019-02-20

Similar Documents

Publication Publication Date Title
US20200375975A1 (en) Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus
TWI607754B (zh) 醫藥組合
TWI649081B (zh) 治療固態腫瘤之方法
US12226409B2 (en) Treatment of hepatocellular carcinoma
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
US20210353648A1 (en) Grapiprant unit dosage forms
CA3019682A1 (fr) Traitement du carcinome a cellules renales a l'aide de lenvatinib et d'everolimus
WO2021026454A1 (fr) Méthode de traitement du cancer
JP2020023497A (ja) 組合せ医薬
US20190142819A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
RU2785893C2 (ru) Лечение почечно-клеточной карциномы ленватинибом и эверолимусом
US20250177414A1 (en) Combination therapies for treatment of breast cancer
Pal et al. Regorafenib (stivarga): a new option in the treatment of patients with metastatic colorectal cancer (CRC)
WO2024015506A1 (fr) Méthodes de traitement de troubles médiés par les récepteurs des oestrogènes
WO2024076626A1 (fr) Méthodes de traitement de troubles médiés par le récepteur des oestrogènes
WO2023059714A1 (fr) Méthodes de traitement de troubles à médiation par les récepteurs des œstrogènes
KR20240138069A (ko) 프탈라지논 유도체를 포함하는 항암제와의 병용 투여용 약학적 조성물
Lombardi et al. REGOMA: A Randomized, Multicenter, Controlled Open-Label Phase II Clinical Trial of Regorafenib Compared to Lomustine in Relapsed Glioblastoma Patients
CA3160121A1 (fr) Inhibiteurs du recepteur des androgenes pour le traitement du cancer de la prostate non metastatique resistant a la castration chez des sujets presentant une deficience hepatique grave
HK40111558A (zh) 与抗癌药物共同施用的包含酞嗪酮衍生物的药物组合物
HK40087811A (zh) 用於治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂
HK1253277B (zh) Ep4受体拮抗剂用於治疗nash相关肝癌的用途
CN109195606A (zh) 用于治疗晚期非小细胞肺癌的方法和组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220414

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240806

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251006

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251208